Limit up during the day and a warning at night? JiangSu WuZhong Pharmaceutical Development's annual report may receive an audit report with an inability to express an opinion | Quick read of the announcement.
① Due to various reasons such as overdue accounts receivable and receivables overdue in the trade business, JiangSu WuZhong Pharmaceutical Development does not rule out the possibility of receiving an audit report expressing an inability to issue an opinion in the 2024 report. ② In addition to being investigated for violations of information disclosure and multiple Bearish factors, JiangSu WuZhong is currently in a precarious situation.
Jointown Pharmaceutical Group invested 0.673 billion to participate in the restructuring, planning to "take control" of Special Treat Meigu and increase investment in medical aesthetics?| Quick read of the announcement.
① Jointown Pharmaceutical Group plans to invest 0.673 billion yuan to participate in the restructuring of Aoyuan Meigu; ② In recent years, Jointown Pharmaceutical Group's medical aesthetics business has grown rapidly and has established partnerships with many domestic medical aesthetics giants, clearly indicating an intention to strengthen this sector.
Olin Bio: The recombinant golden staph vaccine is expected to be mass-produced in 2027. There is still considerable market space for the adsorbed tetanus vaccine | Directly focus on the Shareholder meeting.
① From Olin's 2024 annual performance, both revenue and net income attributable to the parent company have achieved year-on-year growth. The annual sales revenue of the adsorbed tetanus vaccine has exceeded 0.5 billion yuan for the first time; ② A relevant person in charge of the company stated that among the four major "super bacteria" vaccines currently being researched, the recombinant Staphylococcus aureus vaccine will complete the clinical phase III enrollment and is expected to achieve mass production by 2027.
In 2024, Shanghai Yizhong's Net income decreased sharply by 95.68% year-on-year. Core products are included in medical insurance, but performance is under pressure.
① Despite the successful inclusion of core products in the national medical insurance directory, due to factors such as market access difficulties and increased R&D investment, Shanghai Yizhong's revenue and Net income are expected to decline significantly in 2024; ② Shanghai Yizhong stated that it will continue to promote the expansion of indications and the construction of marketing networks to break through market bottlenecks.
Sunshine Guojian Pharmaceutical: Q1 revenue grew by 16.6%, with several positive developments in the R&D pipeline.
Sunshine Guojian Pharmaceutical's Q1 revenue grew by 16.6%, with multiple positive developments in the R&D pipeline. Summary of key points: Financial performance: Q1 revenue in 2025 was 0.311 billion...
Express News | Hong Kong biotechnology stocks surged initially, with Genscript Biotech rising over 18%, Liatris Pharma and REMEGEN rising over 10%, and ZAI LAB rising over 6%.